Mitigation Strategies Successfully Reduce Incidence of Adverse Effects After CAR-T With Ciltacabtagene Autoleucel
Researchers sought to identify predictors of movement and neurocognitive treatment-emergent adverse events in patients undergoing CAR-T therapy with ciltacabtagene autoleucel.